# Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19

> **NCT04470544** · PHASE2 · COMPLETED · sponsor: **Alan Bryce** · enrollment: 100 (actual)

## Conditions studied

- Severe Acute Respiratory Syndrome

## Interventions

- **DRUG:** Camostat Mesilate
- **OTHER:** Standard of Care

## Key facts

- **NCT ID:** NCT04470544
- **Lead sponsor:** Alan Bryce
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-28
- **Primary completion:** 2021-12-22
- **Final completion:** 2022-01-20
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2024-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04470544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04470544, "Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04470544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*